IP Library Granted Patent US 6,909,029
Granted Patent B2
US 6,909,029 · App. 09/963,990 · Granted Jun 21, 2005

Caenorhabditis elegans chemosensory bioassay for seven transmembrane receptor ligands

Assignee: SmithKline Beecham Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,909,029
App. No.
09/963,990
Granted
Jun 21, 2005
Kind
B2
Abstract

This invention relates to methods for producing a transgenic C. elegans that expresses a human 7TMR pan-neuronally, such that said transgenic C. elegans exhibits a known phenotype. These transgenic C. elegans can be used in a variety of ways, including, but not limited to: (1) screening and identifying substances that bind to and activate particular human 7TMRs; (2) screening for substances that antagonize human 7TMR activation; (3) identifying human 7TMRs that may respond to particular substances; and (4) evaluating the specificity and efficacy of substances on human 7TMR activation.

Claims (14)

1. A method for identifying at least one test substance that is an antagonist of a human 7 transmembrane receptor (h7TMR), said method comprising the steps of:

(a) providing at least one transgenic C. elegans whose genome comprises a nucleotide sequence encoding a h7TMR, wherein said h7TMR is expressed in sensory neurons of said transgenic C. elegans , and wherein said sensory neurons correlate with behavior, and wherein said transgenic C. elegans exhibits a phenotype;

(b) contacting said at least one transgenic C. elegans with at least one test substance, wherein said at least one test substance is distributed in a medium;

(c) determining whether said at least one test substance causes a suppression of said phenotype in said at least one transgenic C. elegans ; and

(d) identifying said at least one test substance that causes a suppression of said phenotype in said at least one transgenic C. elegans as an antagonist of said 7TMR.

2. The method as claimed in claim 1 , wherein said behavior is volatile chemoattraction, and said sensory neurons are AWA neurons.

3. The method as claimed in claim 1 , wherein said behavior is volatile chemorepulsion, and said sensory neurons are AWB neurons.

4. The method as claimed in claim 1 , wherein said behavior is water-soluble chemoattraction, and said sensory neurons are chosen from the group of: ASE, ADF, ASG, and ASI neurons.

5. The method as claimed in claim 1 , wherein said behavior is water-soluble chemorepulsion, and said sensory neurons are selected from the group consisting of: ASH and ADL neurons.

6. The method as claimed in claim 1 , wherein said behavior is dauer formation, and said sensory neurons are selected from the group consisting of: ASI, ASG, and ADF neurons.

7. The method as claimed in claim 1 , wherein said behavior is chosen from the group of: thermoattraction and thermorepulsion, and said sensory neurons are AFD neurons.

8. The method as claimed in claim 1 , wherein the medium is chosen from the group of: buffer, growth medium, and agar.

9. The method as claimed in claim 1 , wherein the medium is a growth medium that comprises a biomolecular separation in a matrix.

10. The method as claimed in claim 1 , wherein said matrix is chosen from the group of: agarose and polyacrylamide.

Assignments (2)
CHANGE OF NAME Recorded Mar 10, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 024055/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2001
From: LIVI, GEORGE P.; SHELTON, CHRISTOPHER
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 012229/0232 →
Continuity (2)
Provisional Application 6023729000 · Oct 2, 2000
Related Publication 20020124275A1 · Sep 5, 2002